US Stocks Move: Merck surges on October 29—Q3 beats expectations, guidance raised, plus Keytruda

Merck October 29th Surge Analysis

Keywords: Q3 surpasses expectations, guidance raised, Keytruda

1. On October 29th, Merck announced third-quarter revenue of $18.09 billion, higher than institutional expectations of $17.33 billion; non-GAAP earnings per share were $2.49, exceeding the expected $2.09.

2. On October 29th, the company raised its full-year 2026 adjusted earnings per share guidance to $2.77–$2.82, up from the previous $2.66–$2.76; revenue guidance was narrowed to $66.8–$67.3 billion, with a midpoint of $67.05 billion.

3. On October 29th, Keytruda/Keytruda Qlex sales reached $8.6 billion, up 6% year-on-year, with Keytruda Qlex accounting for $830 million in sales; Winrevair sales were $694 million, a 93% year-on-year increase; Gardasil/Gardasil 9 sales were around $2 billion, up 14% excluding the impact of currency exchange rates; Animal Health sales were $1.7 billion, a 4% increase.

(Disclaimer: This content is generated by AI summarizing publicly available information for reference only and does not constitute investment advice.)